U.S. patent application number 15/997300 was filed with the patent office on 2018-10-04 for methods and devices for using isoperillyl alcohol.
The applicant listed for this patent is NeOnc Technologies, Inc.. Invention is credited to Thomas Chen, Daniel Anthony Dickman, Daniel Levin, Satish Pupalli.
Application Number | 20180280317 15/997300 |
Document ID | / |
Family ID | 46245128 |
Filed Date | 2018-10-04 |
United States Patent
Application |
20180280317 |
Kind Code |
A1 |
Chen; Thomas ; et
al. |
October 4, 2018 |
METHODS AND DEVICES FOR USING ISOPERILLYL ALCOHOL
Abstract
The present invention provides for a method of treating a
disease such as cancer, comprising the step of administering to a
patient a therapeutically effective amount of an isomer or analog
of monoterpene or sesquiterpene (or its derivative), such as an
isoperillyl alcohol. The present invention also provides for a
method of treating a disease comprising the step of administering
to a patient a therapeutically effective amount of a derivative of
an isomer or analog of monoterpene or sesquiterpene, such as an
isoperillyl alcohol carbamate. The derivative may be an isoperillyl
alcohol conjugated with a therapeutic agent such as a
chemotherapeutic agent. The route of administration may vary,
including inhalation, intranasal, oral, transdermal, intravenous,
subcutaneous or intramuscular injection.
Inventors: |
Chen; Thomas; (La Canada,
CA) ; Levin; Daniel; (La Canada, CA) ;
Pupalli; Satish; (Rancho Cucamonga, CA) ; Dickman;
Daniel Anthony; (San Ramon, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
NeOnc Technologies, Inc. |
Los Angeles |
CA |
US |
|
|
Family ID: |
46245128 |
Appl. No.: |
15/997300 |
Filed: |
June 4, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14833210 |
Aug 24, 2015 |
9987237 |
|
|
15997300 |
|
|
|
|
13993910 |
Aug 26, 2013 |
9211269 |
|
|
PCT/US11/65513 |
Dec 16, 2011 |
|
|
|
14833210 |
|
|
|
|
61436365 |
Jan 26, 2011 |
|
|
|
61424332 |
Dec 17, 2010 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 31/325 20130101;
A61K 31/045 20130101; A61P 43/00 20180101; A61K 31/415 20130101;
A61P 35/00 20180101; A61K 31/4188 20130101; C07B 2200/07 20130101;
A61K 47/55 20170801; A61K 45/06 20130101; A61K 31/165 20130101;
A61P 25/00 20180101; C07C 271/22 20130101; A61N 5/10 20130101; A61K
47/54 20170801; C07D 207/26 20130101; C07D 231/12 20130101; C07D
487/04 20130101; A61K 31/05 20130101; A61K 31/4015 20130101; A61K
31/165 20130101; A61K 2300/00 20130101; A61K 31/05 20130101; A61K
2300/00 20130101; A61K 31/415 20130101; A61K 2300/00 20130101; A61K
31/4188 20130101; A61K 2300/00 20130101 |
International
Class: |
A61K 31/045 20060101
A61K031/045; A61K 47/54 20060101 A61K047/54; A61K 31/05 20060101
A61K031/05; C07D 207/26 20060101 C07D207/26; C07D 487/04 20060101
C07D487/04; C07D 231/12 20060101 C07D231/12; C07C 271/22 20060101
C07C271/22; A61N 5/10 20060101 A61N005/10; A61K 31/4015 20060101
A61K031/4015; A61K 47/55 20060101 A61K047/55; A61K 45/06 20060101
A61K045/06; A61K 31/165 20060101 A61K031/165; A61K 31/415 20060101
A61K031/415; A61K 31/4188 20060101 A61K031/4188; A61K 31/325
20060101 A61K031/325 |
Claims
1. A method for treating a disease in a mammal, comprising the step
of administering to the mammal a therapeutically effective amount
of an isoperillyl alcohol.
2. The method of claim 1, wherein the isoperillyl alcohol is
selected from the group consisting of (4-isopropylidene
cyclohex-1-enyl)methanol, (4-isopropyl
cyclohexa-1,3-dienyl)methanol, (4-isopropyl
cyclohexa-1,4-dienyl)methanol, (4-isopropylphenyl)methanol and
(4-isopropenylphenyl)methanol.
3. The method of claim 1, wherein the disease is cancer.
4. The method of claim 3, wherein the cancer is a tumor of the
nervous system.
5. The method of claim 4, wherein the tumor is a glioblastoma.
6. The method of claim 1, further comprising the step of treating
the mammal with radiation.
7. The method of claim 6, wherein the isoperillyl alcohol is
administered before, during or after radiation.
8. The method of claim 1, further comprising the step of
administering to the mammal a chemotherapeutic agent.
9. The method of claim 8, wherein the isoperillyl alcohol is
administered before, during or after the administration of the
chemotherapeutic agent.
10. The method of claim 1, wherein the isoperillyl alcohol is
administered by inhalation, intranasally, orally, intravenously,
subcutaneously or intramuscularly.
11. A method for treating a disease in a mammal, comprising the
step of administering to the mammal a therapeutically effective
amount of an isoperillyl alcohol carbamate.
12. The method of claim 11, wherein the disease is cancer.
13. The method of claim 12, wherein the cancer is a tumor of the
nervous system.
14. The method of claim 13, wherein the tumor is a
glioblastoma.
15. The method of claim 11, further comprising the step of treating
the mammal with radiation.
16. The method of claim 11, further comprising the step of
administering to the mammal a chemotherapeutic agent.
17. The method of claim 11, wherein the isoperillyl alcohol
carbamate is administered by inhalation, intranasally, orally,
intravenously, subcutaneously or intramuscularly.
18. The method of claim 11, wherein the isoperillyl alcohol
carbamate is an isoperillyl alcohol conjugated with a therapeutic
agent.
19. The method of claim 18, wherein the therapeutic agent is a
chemotherapeutic agent.
20. The method of claim 19, wherein the chemotherapeutic agent is
selected from the group consisting of a DNA alkylating agent, a
topoisomerase inhibitor, an endoplasmic reticulum stress inducing
agent, a platinum compound, an antimetabolite, an enzyme inhibitor,
and a receptor antagonist.
21. The method of claim 18, wherein the therapeutic agent is
selected from the group consisting of dimethyl celocoxib (DMC),
temozolomide (TMZ) and rolipram.
22. A method for treating a disease in a mammal, comprising the
step of administering to the mammal a therapeutically effective
amount of an isoperillyl alcohol or an isoperillyl alcohol
carbamate using a nasal delivery device.
23. The method of claim 22, wherein the nasal delivery device is
selected from the group consisting of an intranasal inhaler, an
intranasal spray device, an atomizer, a nebulizer, a metered dose
inhaler (MDI), a pressurized dose inhaler, an insufflator, a unit
dose container, a pump, a dropper, a squeeze bottle and a
bi-directional device.
24. A pharmaceutical composition comprising an isoperillyl alcohol
carbamate.
25. The pharmaceutical composition of claim 24, wherein the
isoperillyl alcohol carbamate is an isoperillyl alcohol conjugated
with a therapeutic agent.
26. The pharmaceutical composition of claim 25, wherein the
therapeutic agent is a chemotherapeutic agent.
27. The pharmaceutical composition of claim 25, wherein the
therapeutic agent is selected from the group consisting of dimethyl
celocoxib (DMC), temozolomide (TMZ) and rolipram.
28. The pharmaceutical composition of claim 25, wherein the
chemotherapeutic agent is selected from the group consisting of a
DNA alkylating agent, a topoisomerase inhibitor, an endoplasmic
reticulum stress inducing agent, a platinum compound, an
antimetabolite, an enzyme inhibitor, and a receptor antagonist.
29. The pharmaceutical composition of claim 24, wherein the
pharmaceutical composition is administered by inhalation,
intranasally, orally, intravenously, subcutaneously or
intramuscularly.
30. The pharmaceutical compoMtion of claim 24, wherein the
pharmaceutical composition is admixed or coformulated with a
therapeutic agent.
31. A pharmaceutical composition comprising an isoperillyl alcohol
admixed or coformulated with a therapeutic agent.
32. A process for making an isoperillyl alcohol carbamate,
comprising the step of reacting a first reactant of isoperillyl
chloroformate with a second reactant selected from the group
consisting of dimethyl celocoxib (DMC), temozolomide (TMZ) and
rolipram.
33. The process of claim 32, wherein the second reactant is
dimethyl celocoxib.
34. The process of claim 32, wherein the reaction is carried out in
the presence of acetone and a catalyst of potassium carbonate.
35. The process of claim 32, wherein the second reactant is
rolipram.
36. The process of claim 35, wherein the reaction is carried out in
the presence of tetrahydrofuran and a catalyst of n-butyl
lithium.
37. The process of claim 32, wherein isoperillyl chloroformate is
prepared by reacting isoperillyl alcohol with phosgene.
Description
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application is a continuation of U.S. patent
application Ser. No. 14/833,210 filed Aug. 24, 2015, which is a
continuation of U.S. application Ser. No. 13/993,910 filed Aug. 26,
2013, now U.S. Pat. No. 9,211,269, which is a U.S. National Stage
of PCT/US11/65513 filed Dec. 16, 2011, which claims benefit of U.S.
Provisional Application No. 61/436,365 filed Jan. 26, 2011 and U.S.
Provisional Application No. 61/424,332 filed Dec. 17, 2010.
FIELD OF THE INVENTION
[0002] The present invention relates to isoperillyl alcohol
(iso-POH) and isoperillyl alcohol derivatives. Isoperillyl alcohol
includes any isomers or analogs of perillyl alcohol. The present
invention further relates to methods of using isoperillyl alcohol
and isoperillyl alcohol derivatives such as isoperillyl alcohol
carbamates to treat cancer.
BACKGROUND OF THE INVENTION
[0003] Malignant gliomas, the most common form of central nervous
system (CNS) cancers, are currently considered essentially
incurable. Among the various malignant gliomas, anaplastic
astrocytomas (Grade III) and glioblastoma multiforme (GBM; Grade
IV) have an especially poor prognosis due to their aggressive
growth and resistance to currently available therapies. The present
standard of care for malignant gliomas consists of surgery,
ionizing radiation, and chemotherapy. Despite recent advances in
medicine, the past 50 years have not seen any significant
improvement in prognosis for malignant gliomas. Wen et al.
Malignant gliomas in adults. New England J Med. 359: 492-507, 2008.
Stupp et al. Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma. New England J Med. 352: 987-996,
2005.
[0004] The poor response of tumors, including malignant gliomas, to
various types of chemotherapeutic agents are often due to intrinsic
drug resistance. Additionally, acquired resistance of initially
well-responding tumors and unwanted side effects are other problems
that frequently thwart long-term treatment using chemotherapeutic
agents. Hence, various analogues of chemotherapeutic agents have
been prepared in an effort to overcome these problems. The
analogues include novel therapeutic agents which are hybrid
molecules of at least two existing therapeutic agents. For example,
cisplatin has been conjugated with cytotoxic codrugs, or conjugated
with bioactive shuttle components such as porphyrins, bile acids,
hormones, or modulators that expedite the transmembrane transport
or the drug accumulation within the cell. (6-Aminomethylnicotinate)
dichloridoplatinum (II) complexes esterified with terpene alcohols
were tested on a panel of human tumor cell lines. The terpenyl
moieties in these complexes appeared to fulfill a transmembrane
shuttle function and increased the rate and extent of the uptake of
these conjugates into various tumor cell lines. Schobert et al.
Monoterpenes as Drug Shuttles: Cytotoxic (6-minomethylnicotinate)
dichloridoplatinum(II) Complexes with Potential To Overcome
Cisplatin Resistance. J. Med. Chem. 2007, 50, 1288-1293.
[0005] Perillyl alcohol (POH), a naturally occurring monoterpene,
has been suggested to be an effective agent against a variety of
cancers, including CNS cancer, breast cancer, pancreatic cancer,
lung cancer, melanomas and colon cancer. Gould, M. Cancer
chemoprevention and therapy by monoterpenes. Environ Health
Perspect. 1997 June; 105 (Suppl 4): 977-979. Hybrid molecules
containing both perillyl alcohol and retinoids were prepared to
increase apoptosis-inducing activity. Das et al. Design and
synthesis of potential new apoptosis agents: hybrid compounds
containing perillyl alcohol and new constrained retinoids.
Tetrahedron Letters 2010, 51, 1462-1466.
[0006] In order to improve performance over perillyl alcohol and
its derivatives, there is a need to prepare isomers or analogs
including isoperillyl alcohol conjugated with other therapeutic
agents, and use this material in the treatment of cancers such as
malignant gliomas, as well as other brain disorders such as
Parkinson's and Alzheimer's disease. These compounds may be
administered alone or in combination with other treatment methods
including radiation, standard chemotherapy, and surgery. The
administration can also be through various routes including
intranasal, oral, oral-tracheal for pulmonary delivery, and
transdermal.
SUMMARY OF THE INVENTION
[0007] The invention provides for a method for treating a disease
in a mammal, comprising the step of delivering to the mammal a
therapeutically effective amount of an isoperillyl alcohol. The
invention also provides for a method for treating a disease in a
mammal, comprising the step of delivering to the mammal a
therapeutically effective amount of an isoperillyl alcohol
carbamate. The method may further comprise the step of treating the
mammal with radiation, and/or further comprise the step of
delivering to the mammal a chemotherapeutic agent. The diseases
treated may be cancer, including a tumor of the nervous system,
such as a glioblastoma. The routes of administration include
inhalation, intranasal, oral, intravenous, subcutaneous or
intramuscular administration.
[0008] The present invention further provides for a pharmaceutical
composition comprising an isoperillyl alcohol carbamate. The
isoperillyl alcohol carbamate may be isoperillyl alcohol conjugated
with a therapeutic agent, such as a chemotherapeutic agent. The
chemotherapeutic agents that may be used in the present invention
include a DNA alkylating agent, a topoisomerase inhibitor, an
endoplasmic reticulum stress inducing agent, a platinum compound,
an antimetabolite, an enzyme inhibitor, and a receptor antagonist.
In certain embodiments, the therapeutic agents are dimethyl
celocoxib (DMC), temozolomide (TMZ) or rolipram. The present
invention provides for a pharmaceutical composition comprising an
isoperillyl alcohol admixed or coformulated with a therapeutic
agent. The pharmaceutical compositions of the present invention may
be administered before, during or after radiation. The
pharmaceutical compositions may be administered before, during or
after the administration of a chemotherapeutic agent.
[0009] The present invention also provides for a process for making
an isoperillyl alcohol carbamate, comprising the step of reacting a
first reactant of isoperillyl chloroformate with a second reactant,
which may be dimethyl celocoxib (DMC), temozolomide (TMZ) or
rolipram. When the second reactant is dimethyl celocoxib, the
reaction may be carried out in the presence of acetone and a
catalyst of potassium carbonate. When the second reactant is
rolipram, the reaction may be carried out in the presence of
tetrahydrofuran with n-butyl lithium. The isoperillyl chloroformate
may also be prepared by reacting isoperillyl alcohol with
phosgene.
BRIEF DESCRIPTION OF THE DRAWINGS
[0010] FIG. 1 shows the results of the MTT cytotoxicity assays
demonstrating the efficacy of different types of POH and iso-POH in
killing LN229 human glioma cells.
[0011] FIG. 2 shows the results of the MTT cytotoxicity assays
demonstrating the efficacy of different types of POH and iso-POH in
killing U251 human glioma cells.
[0012] FIG. 3 shows the results of the MTT cytotoxicity assays
demonstrating the efficacy of different types of POH and iso-POH in
killing A172 human glioma cells.
[0013] FIGS. 4A and 4B show the results of the MU cytotoxicity
assays demonstrating the efficacy of different types of POH and
iso-POH in killing A172 human glioma cells (temozolomide-sensitive)
(FIG. 4A) and A172 temozolomide-resistant cells (FIG. 4B).
SGP-527-155 is the POH purified to the GLP quality (with a GC
relative area purity (area under the curve) of about 98.7%).
SGP-561-79P and SGP-561-65P are two different batches of Iso-POH.
SGP-561-79P is more purified than SGP-561-65P and the details are
as follows.
TABLE-US-00001 GC analysis HPLC analysis Impur- Impur- ity ity
Sample Purity Assay (RRT: Purity Assay (RRT: Ref # (AUC) (wt %)
0.8) (AUC) (wt %) 1.08) SGP-561-65P 95.8% NA 2.1% NA NA NA
SGP-561-79P 93.6% 97.6% 0.71% 98.8% 104% 0.73% * NA: Not analyzed
Note: Due to the decomposition of the sample by the GC analysis, we
have analyzed the Iso-POH by HPLC and compared it with
Sigma-Aldrich POH as a standard for wt % assay. Sigma POH is the
POH purchased from Sigma Chemicals.
[0014] FIGS. 5A and 5B show the results of the MIT cytotoxicity
assays demonstrating the efficacy of different types of POH and
iso-POH in killing U251 human glioma cells (temozolomide-sensitive)
(FIG. 5A) and U251 temozolomide-resistant cells (FIG. 5B).
[0015] FIGS. 6A and 6B show the results of the MIT cytotoxicity
assays demonstrating the efficacy of different types of POH and
iso-POH in killing LN229 human glioma cells
(temozolomide-sensitive) (FIG. 6A) and LN229 temozolomide-resistant
cells (FIG. 6B).
[0016] FIGS. 7A and 7B show the results of the MTT cytotoxicity
assays demonstrating the efficacy of different types of POH and
iso-POH in killing U87 human glioma cells (temozolomide-sensitive)
(FIG. 7A) and U87 temozolomide-resistant cells (FIG. 7B).
[0017] FIGS. 8A, 8B and 8C show the results of the MTT cytotoxicity
assays demonstrating the efficacy of different types of POH and
iso-POH in killing U251 human glioma cells (temozolomide-sensitive)
(FIG. 8A) and U251 temozolomide-resistant cells (FIGS. 8B and 8C).
U251-TR1 and U251-TR1 refer to two temozolomide-resistant U251 cell
lines. Sigma POH is the POH purchased from Sigma Chemicals. GLP POH
is the POH purified to the GLP quality (with a GC relative area
purity (area under the curve) of about 98.7%). Iso-POH65 and
Iso-POH79 are different batches of iso-POH (see details above for
FIGS. 4A and 4B).
[0018] FIG. 9 shows the results of the MTT cytotoxicity assays
demonstrating the efficacy of POH and iso-POH in killing USC04
glioblastoma cancer stem cell line.
[0019] FIGS. 10A and 10B show Western blot performed after an
18-hour treatment of U251 glioma cells with Sigma POH (1.5 mM,
having a purity of about 95% (AUC)) or ultrapure POH ("GLP-POH",
1.5 mM; having a purity of about 98.7% (AUC)) in both U251
TMZ-sensitive and TMZ-resistant (U251-TR1, U251-TR2) cells
demonstrating increased expression of glucose-regulatory protein 78
(GRP-78) and the apoptosis marker CHOP, showing increased
endoplasmic reticulum (ER) stress after treatment (FIG. 10A). Under
the same conditions, iso-POH (iso-POH65, iso-POH79) also increased
ER stress (FIG. 10B).
[0020] FIG. 11 shows Western blot performed after a 24-hour
treatment of U251 glioma cells with 500 .mu.M Sigma POH, GLP POH or
iso-POH (isoPOH65, isoPOH79) demonstrating that all treatments
decreased Kras expression.
DETAILED DESCRIPTION OF THE INVENTION
[0021] The present invention provides for methods of treating a
disease such as cancer using an isoperillyl alcohol or a derivative
of an isoperillyl alcohol. Routes of administration include
inhalation, intranasal, oral, transdermal, intravenous,
subcutaneous and intramuscular injection.
[0022] In the present methods, a patient is administered a
therapeutically effective amount of an isomer or analog of
monoterpene or sesquiterpene, such as an isoperillyl alcohol. The
present invention also provides for a method of treating a disease
comprising the step of administering to a patient a therapeutically
effective amount of a derivative of an isomer or analog of
monoterpene or sesquiterpene, such as an isoperillyl alcohol
carbamate. The derivative may be an isoperillyl alcohol conjugated
with a therapeutic agent such as a chemotherapeutic agent.
[0023] For example, the isomer or analog of monoterpene or
sesquiterpene can be an isoperillyl alcohol (iso-POH). Isoperillyl
alcohols include any isomers or analogs of perillyl alcohol. In one
embodiment, the isoperillyl alcohol is (4-isopropylidene
cyclohex-1-enyl)methanol. Other examples of isoperillyl alcohol
include, but are not limited to, (4-isopropyl
cyclohexa-1,3-dienyl)methanol, (4-isopropyl
cyclohexa-1,4-dienyl)methanol, (4-isopropylphenyl)methanol and
(4-isopropenylphenyl)methanol.
[0024] An exemplary isoperillyl alcohol, (4-isopropylidene
cyclohex-1-enyl)methanol, is shown below:
##STR00001##
[0025] The compounds of the present invention may be used for the
treatment of nervous system cancers, such as a malignant glioma
(e.g., astrocytoma, anaplastic astrocytoma, glioblastoma
multiforme), retinoblastoma, pilocytic astrocytomas (grade I),
meningiomas, metastatic brain tumors, neuroblastoma, pituitary
adenomas, skull base meningiomas, and skull base cancer. The
present invention also provides methods of treating CNS (central
nervous system) disorders, including, without limitation, primary
degenerative neurological disorders such as Alzheimer's,
Parkinson's, psychological disorders, psychosis and depression.
[0026] Also encompassed by the present invention is a derivative of
an isomer or analog of monoterpene or sesquiterpene, such as an
isoperillyl alcohol derivative. For example, the isoperillyl
alcohol derivative may be an isoperillyl alcohol carbamate, ester,
or ether. The derivative of an isomer or analog of monoterpene or
sesquiterpene may be an isomer or analog of monoterpene or
sesquiterpene conjugated with a therapeutic agent such as a
chemotherapeutic agent. The isoperillyl alcohol derivative may be
isoperillyl alcohol conjugated with a therapeutic agent such as a
chemotherapeutic agent.
[0027] The compounds of the present invention thus include both
isomers or analogs of monoterpene or sesquiterpene, and derivatives
of an isomer or analog of monoterpene or sesquiterpene. The isomer
or analog of monoterpene or sesquiterpene (or the derivative of an
isomer or analog of monoterpene or sesquiterpene), may be
formulated into a pharmaceutical composition, where the isomer or
analog of monoterpene or sesquiterpene (or the derivative of an
isomer or analog of monoterpene or sesquiterpene), is present in
amounts ranging from about 0.01% (w/w) to about 100% (w/w), from
about 0.1% (w/w) to about 80% (w/w), from about 1% (w/w) to about
70% (w/w), from about 10% (w/w) to about 60% (w/w), or from about
0.1% (w/w) to about 20% (w/w). The present compositions can be
administered alone, or may be co-administered together with
radiation or another agent (e.g., a chemotherapeutic agent), to
treat a disease such as cancer. Treatments may be sequential, with
isomer or analog of monoterpene or sesquiterpene (or the derivative
of an isomer or analog of monoterpene or sesquiterpene) being
administered before or after the administration of other agents.
For example, an isoperillyl alcohol (or an isoperillyl alcohol
carbamate, ester, or ether) may be used to sensitize a cancer
patient to radiation or chemotherapy. Alternatively, agents may be
administered concurrently. The route of administration may vary,
and can include, inhalation, intranasal, oral, transdermal,
intravenous, subcutaneous or intramuscular injection.
[0028] The compositions of the present invention may contain one or
more types of isomers or analogs of monoterpene or sesquiterpene
(or the derivatives of isomers or analogs of monoterpene or
sesquiterpene). Monoterpenes include terpenes that consist of two
isoprene units. Monoterpenes may be linear (acyclic) or contain
rings. Derivatives of monoterpenoids are also encompassed by the
present invention. Monoterpenoids may be produced by biochemical
modifications such as oxidation or rearrangement of monoterpenes.
Examples of monoterpenes and monoterpenoids include, perillyl
alcohol (S(-)) and (R(+)), ocimene, myrcene, geraniol, citral,
citronellol, citronellal, linalool, pinene, terpineol, terpinen,
limonene, terpinenes, phellandrenes, terpinolene, terpinen-4-ol (or
tea tree oil), pinene, terpineol, terpinen; the terpenoids such as
p-cymene which is derived from monocyclic terpenes such as menthol,
thymol and carvacrol; bicyclic monoterpenoids such as camphor,
borneol and eucalyptol.
[0029] Monoterpenes may be distinguished by the structure of a
carbon skeleton and may be grouped into acyclic monoterpenes (e.g.,
myrcene, (Z)- and (E)-ocimene, linalool, geraniol, nerol,
citronellol, myrcenol, geranial, citral a, neral, citral b,
citronellal, etc.), monocyclic monoterpenes (e.g., limonene,
terpinene, phellandrene, terpinolene, menthol, carveol, etc.),
bicyclic monoterpenes (e.g., pinene, myrtenol, myrtenal, verbanol,
verbanon, pinocarveol, carene, sabinene, camphene, thujene, etc.)
and tricyclic monoterpenes (e.g. tricyclene). See Encyclopedia of
Chemical Technology, Fourth Edition, Volume 23, page 834-835.
[0030] Sesquiterpenes of the present invention include terpenes
that consist of three isoprene units. Sesquiterpenes may be linear
(acyclic) or contain rings. Derivatives of sesquiterpenoids are
also encompassed by the present invention. Sesquiterpenoids may be
produced by biochemical modifications such as oxidation or
rearrangement of sesquiterpenes. Examples of sesquiterpenes include
farnesol, farnesal, farnesylic acid and nerolidol. U.S. Provisional
Application Nos. 61/310,231 (filed on Mar. 3, 2010), 61/377,747
(filed on Aug. 27, 2010), 61/471,402 (filed on Apr. 4, 2011) and
61/562,105 (filed on Nov. 21, 2011). PCT Application Nos.
PCT/US2011/027051 (filed on Mar. 3, 2011) and PCT/US2011/049392
(filed on Aug. 26, 2011). U.S. application Ser. No. 13/040,059
(filed on Mar. 3, 2011). All these applications are incorporated
herein by reference in their entirety.
[0031] The derivatives of isomers or analogs of monoterpene or
sesquiterpene include, but are not limited to, carbamates, esters,
ethers, alcohols and aldehydes of the monoterpene (or
sesquiterpene). Alcohols may be derivatized to carbamates, esters,
ethers, aldehydes or acids.
[0032] Carbamate refers to a class of chemical compounds sharing
the functional group
##STR00002##
based on a carbonyl group flanked by an oxygen and a nitrogen.
R.sup.1, R.sup.2 and R.sup.3 can be a group such as alkyl, aryl,
etc., which can be substituted. The R groups on the nitrogen and
the oxygen may form a ring. R.sup.1--OH may be a monoterpene, e.g.,
POH. The R.sup.2--N--R.sup.3 moiety may be a therapeutic agent.
[0033] Carbamates may be synthesized by reacting isocyanate and,
alcohol, or by reacting chloroformate with amine. Carbamates may be
synthesized by reactions making use of phosgene or phosgene
equivalents. For example, carbamates may be synthesized by reacting
phosgene gas, diphosgene or a solid phosgene precursor such as
triphosgene with two amines or an amine and an alcohol. Carbamates
(also known as urethanes) can also be made from reaction of a urea
intermediate with an alcohol. Dimethyl carbonate and diphenyl
carbonate are also used for making carbamates. Alternatively,
carbamates may be synthesized through the reaction of alcohol
and/or amine precursors with an ester-substituted diaryl carbonate,
such as bismethylsalicylcarbonate (BMSC). U.S. Patent Publication
No. 20100113819.
[0034] Carbamates may be synthesized by the following approach:
##STR00003##
Suitable reaction solvents include, but are not limited to,
tetrahydrofuran, dichloromethane, dichloroethane, acetone, and
diisopropyl ether. The reaction may be performed at a temperature
ranging from about -70.degree. C. to about 80.degree. C., or from
about -65.degree. C. to about 50.degree. C. The molar ratio of
isoperillyl chloroformate to the substrate R--NH.sub.2 may range
from about 1:1 to about 2:1, from about 1:1 to about 1.5:1, from
about 2:1 to about 1:1, or from about 1.05:1 to about 1.1:1.
Suitable bases include, but are not limited to, organic bases, such
as triethylamine, potassium carbonate, N,N'-diisopropylethylamine,
butyl lithium, and potassium-t-butoxide.
[0035] Alternatively, carbamates may be synthesized by the
following approach:
##STR00004##
Suitable reaction solvents include, but are not limited to,
dichloromethane, dichloroethane, toluene, diisopropyl ether, and
tetrahydrofuran. The reaction may be performed at a temperature
ranging from about 25.degree. C. to about 110.degree. C., or from
about 30.degree. C. to about 80.degree. C., or about 50.degree. C.
The molar ratio of isoperillyl alcohol to the substrate
R--N.dbd.C.dbd.O may range from about 1:1 to about 2:1, from about
1:1 to about 1.5:1, from about 2:1 to about 1:1, or from about
1.05:1 to about 1.1:1.
[0036] Esters of the alcohols of the isomers or analogs of
monoterpene or sesquiterpene can be derived from an inorganic acid
or an organic acid. Inorganic acids include, but are not limited
to, phosphoric acid, sulfuric acid, and nitric acid. Organic acids
include, but are not limited to, carboxylic acid such as benzoic
acid, fatty acid, acetic acid and propionic acid, and any
therapeutic agent bearing at least one carboxylic acid functional
group. Examples of the esters of alcohols include, but are not
limited to, carboxylic acid esters (such as benzoate esters, fatty
acid esters (e.g., palmitate ester, linoleate ester, stearate
ester, butyryl ester and oleate ester), acetates, propionates (or
propanoates), and formates), phosphates, sulfates, and carbamates
(e.g., N,N-dimethylaminocarbonyl). Wikipedia--Ester. Retrieved from
URL: http://en.wikipedia.org/wiki/Ester.
[0037] The derivatives of isoperillyl alcohol include isoperillyl
alcohol carbamates, isoperillyl alcohol esters, isoperillic
aldehydes, isoperillic acid, isoperillic aldehyde derivatives, and
isoperillic acid esters. The derivatives of isoperillyl alcohol may
also include its oxidative and nucleophilic/electrophilic addition
derivatives. Few examples of derivatives of isoperillyl alcohol are
reported in the chemistry literature. See U.S. Pat. No. 5,994,598
and Japanese Patent No. 07048264A.
[0038] In certain embodiments, an iso-POH carbamate is synthesized
by a process comprising the step of reacting a first reactant of
isoperillyl chloroformate with a second reactant such as dimethyl
celocoxib (DMC), temozolomide (TMZ) and rolipram. The reaction may
be carried out in the presence of tetrahydrofuran and a base such
as n-butyl lithium. Isoperillyl chloroformate may be made by
reacting iso-POH with phosgene. For example, iso-POH conjugated
with temozolomide through a carbamate bond may be synthesized by
reacting temozolomide with oxalyl chloride followed by reaction
with isoperillyl alcohol. The reaction may be carried out in the
presence of 1,2-dichloroethane.
[0039] Iso-POH carbamates encompassed by the present invention
include, but are not limited to, (3-Methyl
4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]
tetrazine-8-carbonyl)-carbamic acid-4-isopropylidene
cyclohex-1-enylmethyl ester,
4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-oxo-pyrrolidine-1-carboxylic
acid 4-isopropylidene cyclohex-1-enylmethyl ester,
4-(Bis-N,N'-4-isopropylidene cyclohex-1-enylmethyloxy carbonyl
[5-(2,5-dimethyl phenyl)-3-trifluoromethyl pyrazol-1-yl]
benzenesulfonamide. The details of the chemical reactions
generating these compounds are described in the Examples below.
[0040] In certain embodiments, iso-perillyl alcohol derivatives may
be isoperillyl alcohol fatty acid esters, such as palmitoyl ester
of iso-POH and linoleoyl ester of iso-POH.
[0041] The derivative of an isomer or analog of monoterpene or
sesquiterpene may be an isomer or analog of monoterpene or
sesquiterpene conjugated with a therapeutic agent. A conjugate
encompassed by the present invention is a molecule having an isomer
or analog of monoterpene or sesquiterpene covalently bound via a
chemical linking group to a therapeutic agent. The molar ratio of
the isomer or analog of monoterpene or sesquiterpene to the
therapeutic agent in the conjugate may be 1:1, 1:2, 1:3, 1:4, 2:1,
3:1, 4:1, or any other suitable molar ratios. The isomer or analog
of monoterpene or sesquiterpene and the therapeutic agent may be
covalently linked through carbamate, ester, ether bonds, or any
other suitable chemical functional groups. When the isomer or
analog of monoterpene or sesquiterpene and the therapeutic agent
are conjugated through a carbamate bond, the therapeutic agent may
be any agent bearing at least one carboxylic acid functional group,
or any agent bearing at least one amine functional group. In a
specific example, an isoperillyl alcohol conjugate is isoperillyl
alcohol covalently bound via a chemical linking group to a
chemotherapeutic agent.
[0042] According to the present invention, the therapeutic agents
that may be conjugated with an isomer or analog of monoterpene or
sesquiterpene include, but are not limited to, chemotherapeutic
agents, therapeutic agents for treatment of CNS disorders
(including, without limitation, primary degenerative neurological
disorders such as Alzheimer's, Parkinson's, multiple sclerosis,
Attention-Deficit Hyperactivity Disorder or ADHD, psychological
disorders, psychosis and depression), immunotherapeutic agents,
angiogenesis inhibitors, and anti-hypertensive agents. Anti-cancer
agents that may be conjugated with monoterpene or sesquiterpene can
have one or more of the following effects on cancer cells or the
subject: cell death; decreased cell proliferation; decreased
numbers of cells; inhibition of cell growth; apoptosis; necrosis;
mitotic catastrophe; cell cycle arrest; decreased cell size;
decreased cell division; decreased cell survival; decreased cell
metabolism; markers of cell damage or cytotoxicity; indirect
indicators of cell damage or cytotoxicity such as tumor shrinkage;
improved survival of a subject; or disappearance of markers
associated with undesirable, unwanted, or aberrant cell
proliferation. U.S. Patent Publication No. 20080275057.
[0043] Also encompassed by the present invention are admixtures
and/or coformulations of an isomer or analog of monoterpene or
sesquiterpene and at least one therapeutic agent.
[0044] Chemotherapeutic agents include, but are not limited to, DNA
alkylating agents, topoisomerase inhibitors, endoplasmic reticulum
stress inducing agents, a platinum compound, an antimetabolite,
vincalkaloids, taxanes, epothilones, enzyme inhibitors, receptor
antagonists, tyrosine kinase inhibitors, boron radiosensitizers
(i.e. velcade), and chemotherapeutic combination therapies.
[0045] Non-limiting examples of DNA alkylating agents are nitrogen
mustards, such as Cyclophosphamide (Ifosfamide, Trofosfamide),
Chlorambucil (Melphalan, Prednimustine), Bendamustine, Uramustine
and Estramustine; nitrosoureas, such as Carmustine (BCNU),
Lomustine (Semustine), Fotemustine, Nimustine, Ranimustine and
Streptozocin; alkyl sulfonates, such as Busulfan (Mannosulfan,
Treosulfan); Aziridines, such as Carboquone, Triaziquone,
Triethylenemelamine; Hydrazines (Procarbazine); Triazenes such as
Dacarbazine and Temozolomide; Altretamine and Mitobronitol.
[0046] Non-limiting examples of Topoisomerase l inhibitors include
Campothecin derivatives including SN-38, APC, NPC, campothecin,
topotecan, exatecan mesylate, 9-nitrocamptothecin,
9-aminocamptothecin, lurtotecan, rubitecan, silatecan, gimatecan,
diflomotecan, extatecan, BN-80927, DX-8951 f, and MAG-CPT as
decribed in Pommier Y. (2006) Nat. Rev. Cancer 6(10):789-802 and
U.S. Patent Publication No. 200510250854; Protoberberine alkaloids
and derivatives thereof including berberrubine and coralyne as
described in Li et al. (2000) Biochemistry 39(24):7107-7116 and
Gatto et al. (1996) Cancer Res. 15(12):2795-2800; Phenanthroline
derivatives including Benzo[i]phenanthridine, Nitidine, and
fagaronine as described in Makhey et al. (2003) Bioorg. Med. Chem.
11 (8): 1809-1820; Terbenzimidazole and derivatives thereof as
described in Xu (1998) Biochemistry 37(10):3558-3566; and
Anthracycline derivatives including Doxorubicin, Daunorubicin, and
Mitoxantrone as described in Foglesong et al. (1992) Cancer
Chemother. Pharmacol. 30(2):123-]25, Crow et al. (1994) J. Med.
Chem. 37(19):31913194, and Crespi et al. (1986) Biochem. Biophys.
Res. Commun. 136(2):521-8. Topoisomerase 11 inhibitors include, but
are not limited to Etoposide and Teniposide. Dual topoisomerase I
and II inhibitors include, but are not limited to, Saintopin and
other Naphthecenediones, DACA and other Acridine-4-Carboxamindes,
Intoplicine and other Benzopyridoindoles, TAS-103 and other
7H-indeno[2,1-c]Quinoline-7-ones, Pyrazoloacridine, XR 11576 and
other Benzophenazines, XR 5944 and other Dimeric compounds,
7-oxo-7H-dibenz[f,ij]Isoquinolines and
7-oxo-7H-benzo[e]pyrimidines, and Anthracenyl-amino Acid Conjugates
as described in Denny and Baguley (2003) Curr. Top. Med. Chem.
3(3):339-353. Some agents inhibit Topoisomerase II and have DNA
intercalation activity such as, but not limited to, Anthracyclines
(Aclarubicin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin,
Amrubicin, Pirarubicin, Valrubicin, Zorubicin) and Antracenediones
(Mitoxantrone and Pixantrone).
[0047] Examples of endoplasmic reticulum stress inducing agents
include, but are not limited to, dimethyl-celecoxib (DMC),
nelfinavir, celecoxib, and boron radiosensitizers (i.e. velcade
(Bortezomib)).
[0048] Platinum based compounds are a subclass of DNA alkylating
agents. Non-limiting examples of such agents include Cisplatin,
Nedaplatin, Oxaliplatin, Triplatin tetranitrate, Satraplatin,
Aroplatin, Lobaplatin, and JM-216. (see McKeage et al. (1997) J.
Clin. Oncol. 201:1232-1237 and in general, CHEMOTHERAPY FOR
GYNECOLOGICAL NEOPLASM, CURRENT THERAPY AND NOVEL APPROACHES, in
the Series Basic and Clinical Oncology, Angioli et al. Eds.,
2004).
[0049] "FOLFOX" is an abbreviation for a type of combination
therapy that is used to treat colorectal cancer. It includes 5-FU,
oxaliplatin and leucovorin. Information regarding this treatment is
available on the National Cancer Institute's web site, cancer.gov,
last accessed on Jan. 16, 2008.
[0050] "FOLFOX/BV" is an abbreviation for a type of combination
therapy that is used to treat colorectal cancer. This therapy
includes 5-FU, oxaliplatin, leucovorin and Bevacizumab.
Furthennore, "XELOX/BV" is another combination therapy used to
treat colorectal cancer, which includes the prodrug to 5-FU, known
as Capecitabine (Xeloda) in combination with oxaliplatin and
bevacizumab. Infonnation regarding these treatments are available
on the National Cancer Institute's web site, cancer.gov or from 23
the National Comprehensive Cancer Network's web site, nccn.org,
last accessed on May 27, 2008.
[0051] Non-limiting examples of antimetabolite agents include Folic
acid based, i.e. dihydrofolate reductase inhibitors, such as
Aminopterin, Methotrexate and Pemetrexed; thymidylate synthase
inhibitors, such as Raltitrexed, Pemetrexed; Purine based, i.e. an
adenosine deaminase inhibitor, such as Pentostatin, a thiopurine,
such as Thioguanine and Mercaptopurine, a
halogenated/ribonucleotide reductase inhibitor, such as Cladribine,
Clofarabine, Fludarabine, or a guanine/guanosine: thiopurine, such
as Thioguanine; or Pyrimidine based, i.e. cytosine/cytidine:
hypomethylating agent, such as Azacitidine and Decitabine, a DNA
polymerase inhibitor, such as Cytarabine, a ribonucleotide
reductase inhibitor, such as Gemcitabine, or a thymine/thymidine:
thymidylate synthase inhibitor, such as a Fluorouracil (5-FU).
Equivalents to 5-FU include prodrugs, analogs and derivative
thereof such as 5'-deoxy-5-fluorouridine (doxifluroidine),
1-tetrahydrofuranyl-5-fluorouracil (ftorafur), Capecitabine
(Xeloda), S-I (MBMS-247616, consisting of tegafur and two
modulators, a 5-chloro-2,4-dihydroxypyridine and potassium
oxonate), ralititrexed (tomudex), nolatrexed (Thymitaq, AG337),
LY231514 and ZD9331, as described for example in Papamicheal (1999)
The Oncologist 4:478-487.
[0052] Examples of vincalkaloids, include, but are not limited to
Vinblastine, Vincristine, Vinflunine, Vindesine and
Vinorelbine.
[0053] Examples of taxanes include, but are not limited to
docetaxel, Larotaxel, Ortataxel, Paclitaxel and Tesetaxel. An
example of an epothilone is iabepilone.
[0054] Examples of enzyme inhibitors include, but are not limited
to famesyltransferase inhibitors (Tipifamib); CDK inhibitor
(Alvocidib, Seliciclib); proteasome inhibitor (Bortezomib);
phosphodiesterase inhibitor (Anagrelide; rolipram); IMP
dehydrogenase inhibitor (Tiazofurine); and lipoxygenase inhibitor
(Masoprocol). Examples of receptor antagonists include, but are not
limited to ERA (Atrasentan); retinoid X receptor (Bexarotene); and
a sex steroid (Testolactone).
[0055] Examples of tyrosine kinase inhibitors include, but are not
limited to inhibitors to ErbB: HER1/EGFR (Erlotinib, Gefitinib,
Lapatinib, Vandetanib, Sunitinib, Neratinib); HER2/neu (Lapatinib,
Neratinib); RTK class III: C-kit (Axitinib, Sunitinib, Sorafenib),
FLT3 (Lestaurtinib), PDGFR (Axitinib, Sunitinib, Sorafenib); and
VEGFR (Vandetanib, Semaxanib, Cediranib, Axitinib, Sorafenib);
bcr-abl (Imatinib, Nilotinib, Dasatinib); Src (Bosutinib) and Janus
kinase 2 (Lestaurtinib).
[0056] "Lapatinib" (Tykerb.RTM.) is a dual EGFR and erbB-2
inhibitor. Lapatinib has been investigated as an anticancer
monotherapy, as well as in combination with trastuzumab,
capecitabine, letrozole, paclitaxel and FOLFIRI (irinotecan,
5-fluorouracil and leucovorin), in a number of clinical trials. It
is currently in phase III testing for the oral treatment of
metastatic breast, head and neck, lung, gastric, renal and bladder
cancer.
[0057] A chemical equivalent of lapatinib is a small molecule or
compound that is a tyrosine kinase inhibitor (TKI) or alternatively
a HER-I inhibitor or a HER-2 inhibitor. Several TKIs have been
found to have effective antitumor activity and have been approved
or are in clinical trials. Examples of such include, but are not
limited to, Zactima (ZD6474), Iressa (gefitinib), imatinib mesylate
(STI571; Gleevec), erlotinib (OSI-1774; Tarceva), canertinib (CI
1033), semaxinib (SU5416), vatalanib (PTK787/ZK222584), sorafenib
(BAY 43-9006), sutent (SUI 1248) and lefltmomide (SU101).
[0058] PTK/ZK is a tyrosine kinase inhibitor with broad specificity
that targets all VEGF receptors (VEGFR), the platelet-derived
growth factor (PDGF) receptor, c-KIT and c-Fms. Drevs (2003) Idrugs
6(8):787-794. PTK/ZK is a targeted drug that blocks angiogenesis
and lymphangiogenesis by inhibiting the activity of all known
receptors that bind VEGF including VEGFR-I (Flt-1), VEGFR-2
(KDR/Flk-1) and VEGFR-3 (Flt-4). The chemical names of PTK/ZK are
1-[4-Chloroanilino]-4-[4-pyridylmethyl] phthalazine Succinate or
1-Phthalazinamine,
N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-butanedioate (1:1).
Synonyms and analogs of PTK/TK are known as Vatalanib, CGP79787D,
PTK787/ZK 222584, CGP-79787, DE-00268, PTK-787, PTK787A, VEGFR-TK
inhibitor, ZK 222584 and ZK.
[0059] Chemotherapeutic agents that can be used in admixtures
and/or coformulations and/or conjugated with an isomer or analog of
monoterpene or sesquiterpene may also include amsacrine,
Trabectedin, retinoids (Alitretinoin, Tretinoin), Arsenic trioxide,
asparagine depleter Asparaginase/Pegaspargase), Celecoxib,
Demecolcine, Elesclomol, Elsamitrucin, Etoglucid, Lonidamine,
Lucanthone, Mitoguazone, Mitotane, Oblimersen, Temsirolimus, and
Vorinostat.
[0060] An isomer or analog of monoterpene or sesquiterpene may be
conjugated and/or used in admixtures and/or coformulations with
angiogenesis inhibitors. Examples of angiogenesis inhibitors
include, but are not limited to, angiostatin, angiozyme,
antithrombin III, AG3340, VEGF inhibitors, batimastat, bevacizumab
(avastin), BMS-275291, CAI, 2C3, HuMV833 Canstatin, Captopril,
carboxyamidotriazole, cartilage derived inhibitor (CDI), CC-5013,
6-O-(chloroacetyl-carbonyl)-fumagillol, COL-3, combretastatin,
combretastatin A4 Phosphate, Dalteparin, EMD 121974 (Cilengitide),
endostatin, erlotinib, gefitinib (Iressa), genistein, halofuginone
hydrobromide, Id1, Id3, IM862, imatinib mesylate, IMC-IC11
Inducible protein 10, interferon-alpha, interleukin 12, lavendustin
A, LY317615 or AE-941, marimastat, mspin, medroxpregesterone
acetate, Meth-1, Meth-2, 2-methoxyestradiol (2-ME), neovastat,
oteopontin cleaved product, PEX, pigment epithelium growth factor
(PEGF), platelet factor 4, prolactin fragment, proliferin-related
protein (PRP), PTK787/ZK 222584, ZD6474, recombinant human platelet
factor 4 (rPF4), restin, squalamine, SU5416, SU6668, SU11248
suramin, Taxol, Tecogalan, thalidomide, thrombospondin, TNP-470,
troponin-1, vasostatin, VEG1, VEGF-Trap, and ZD6474.
[0061] Non-limiting examples of angiogenesis inhibitors also
include, tyrosine kinase inhibitors, such as inhibitors of the
tyrosine kinase receptors Flt-1 (VEGFR1) and Flk-1/KDR (VEGFR2),
inhibitors of epidermal-derived, fibroblast-derived, or platelet
derived growth factors, MMP (matrix metalloprotease) inhibitors,
integrin blockers, pentosan polysulfate, angiotensin II
antagonists, cyclooxygenase inhibitors (including non-steroidal
anti-inflammatory drugs (NSAIDs) such as aspirin and ibuprofen, as
well as selective cyclooxygenase-2 inhibitors such as celecoxib and
rofecoxib), and steroidal anti-inflammatories (such as
corticosteroids, mineralocorticoids, dexamethasone, prednisone,
prednisolone, methylpred, betamethasone).
[0062] Other therapeutic agents that modulate or inhibit
angiogenesis and may also be conjugated and/or admixed and/or
coformulated with an isomer or analog of monoterpene or
sesquiterpene include agents that modulate or inhibit the
coagulation and fibrinolysis systems, including, but not limited
to, heparin, low molecular weight heparins and carboxypeptidase U
inhibitors (also known as inhibitors of active thrombin activatable
fibrinolysis inhibitor [TAFIa]). U.S. Patent Publication No.
20090328239. U.S. Pat. No. 7,638,549.
[0063] Non-limiting examples of the anti-hypertensive agents
include angiotensin converting enzyme inhibitors (e.g., captopril,
enalapril, delapril etc.), angiotensin II antagonists (e.g.,
candesartan cilexetil, candesartan, losartan (or Cozaar), losartan
potassium, eprosartan, valsartan (or Diovan), termisartan,
irbesartan, tasosartan, olmesartan, olmesartan medoxomil etc.),
calcium antagonists (e.g., manidipine, nifedipine, amlodipine (or
Amlodin), efonidipine, nicardipine etc.), diuretics, renin
inhibitor (e.g., aliskiren etc.), aldosterone antagonists (e.g.,
spironolactone, eplerenone etc.), beta-blockers (e.g., metoprolol
(or Toporol), atenolol, propranolol, carvedilol, pindolol etc.),
vasodilators (e.g., nitrate, soluble guanylate cyclase stimulator
or activator, prostacycline etc.), angiotensin vaccine, clonidine
and the like. U.S. Patent Publication No. 20100113780.
[0064] Other therapeutic agents that may be conjugated and/or
admixed and/or coformulated with an isomer or analog of monoterpene
or sesquiterpene include, but are not limited to, Sertraline
(Zoloft), Topiramate (Topamax), Duloxetine(Cymbalta), Sumatriptan
(Imitrex), Pregabalin (Lyrica), Lamotrigine (Lamictal),
Valaciclovir (Valtrex), Tamsulosin (Flomax), Zidovudine (Combivir),
Lamivudine (Combivir), Efavirenz (Sustiva), Abacavir (Epzicom),
Lopinavir (Kaletra), Pioglitazone (Actos), Desloratidine
(Clarinex), Cetirizine (Zyrtec), Pentoprazole (Protonix),
Lansoprazole (Prevacid), Rebeprazole (Aciphex), Moxifloxacin
(Avelox), Meloxicam (Mobic), Dorzolamide (Truspot), Diclofenac
(Voltaren), Enlapril (Vasotec), Montelukast (Singulair), Sildenafil
(Viagra), Carvedilol (Coreg), Ramipril (Delix).
[0065] Table 1 lists pharmaceutical agents that can be conjugated
with an isomer or analog of monoterpene or sesquiterpene, including
the structure of the pharmaceutical agent and the preferred
derivative for conjugation.
TABLE-US-00002 TABLE 1 Brand Generic Preferred Name Name Activity
Structure Derivative Zoloft Sertraline Depression ##STR00005##
Carbamate Topamax Topiramate Seizures ##STR00006## Carbamate
Cymbalta Duloxetine Depression ##STR00007## Carbamate Imitrex
Sumatriptan Migraine ##STR00008## Carbamate Lyrica Pregabalin
Neuropathic pain ##STR00009## Carbamate or Ester Lamictal
Lamotrigine Seizures ##STR00010## Carbamate Valtrex Valaciclovir
Herpes ##STR00011## Carbamate Tarceva Erlotinib Non-small cell lung
cancer ##STR00012## Carbamate Flomax Tamsulosin Benign prostatic
Cancer ##STR00013## Carbamate Gleevec Imatinib Leukemia
##STR00014## Carbamate Combivir Zidovudine HIV infection
##STR00015## Carbamate Combivir Lamivudine HIV infection
##STR00016## Carbamate Sustiva Efavirenz HIV infection ##STR00017##
Carbamate Epzicom Abacavir HIV infection ##STR00018## Carbamate
Kaletra Lopinavir HIV infection ##STR00019## Carbamate Actos
Pioglitazone Type-2 diabetes ##STR00020## Carbamate Clarinex
Desloratidine Allergic rhinitis ##STR00021## Carbamate Zyrtec
Cetirizine Allergic ##STR00022## Ester Protonix Pentoprazole
Gastrointestinal ##STR00023## Carbamate Prevacid Lansoprazole
Gastrointestinal ##STR00024## Carbamate Aciphex Rebeprazole
Gastrointestinal ##STR00025## Carbamate Diovan Valsartan
Hypertension ##STR00026## Carbamate Cozaar Losartan Hypertension
##STR00027## Carbamate Avelox Moxifloxacin Bacterial infection
##STR00028## Carbamate or Ester Mobic Meloxicam Osteoarthritis
##STR00029## Carbamate Truspot Dorzolamide Intraocular pressure
##STR00030## Carbamate Voltaren Diclofenac Osteoarthritis &
rheumatoid arthritis ##STR00031## Carbamate or Ester Vasotec
Enlapril Hypertension ##STR00032## Carbamate or Ester Singulair
Montelukast Asthma ##STR00033## Ester Amlodin Amlodipine
Hypertension ##STR00034## Carbamate Toporol Metoprolol Hypertension
##STR00035## Carbamate Viagra Sildenafil Erectile dysfunction
##STR00036## Carbamate Coreg Carvedilol Hypertension ##STR00037##
Carbamate Delix Ramipril Hypertension ##STR00038## Carbamate or
Ester Sinemet (Parcopa, Atamet) L-DOPA Neurological disorders
##STR00039##
[0066] By way of example, an L-DOPA iso-POH conjugate is shown
below:
##STR00040##
[0067] The purity of an isomer or analog of monoterpene or
sesquiterpene, or its derivatives, may be assayed by gas
chromatography (GC) or high pressure liquid chromatography (HPLC).
Other techniques for assaying the purity of the compounds of the
present invention and for determining the presence of impurities
include, but are not limited to, nuclear magnetic resonance (NMR)
spectroscopy, mass spectrometry (MS), GC-MS, infrared spectroscopy
(IR), and thin layer chromatography (TLC). Chiral purity can be
assessed by chiral GC or measurement of optical rotation.
[0068] The isomer or analog of monoterpene or sesquiterpene (or its
derivatives), may be purified by methods such as crystallization,
or by separating the isomer or analog of monoterpene or
sesquiterpene (or its derivative), from impurities according to the
unique physicochemical properties (e.g., solubility or polarity) of
the isomer or analog of monoterpene or sesquiterpene (or its
derivative). Accordingly, the isomer or analog of monoterpene or
sesquiterpene (or its derivative) can be separated by suitable
separation techniques known in the art, such as preparative
chromatography, (fractional) distillation, or (fractional)
crystallization.
[0069] The invention also provides for methods of using an isomer
or analog of monoterpene or sesquiterpene, as well as using a
derivative of an isomer or analog of monoterpene or sesquiterpene,
to treat a disease, such as cancer or other nervous system
disorders. The compounds of the present invention may be
administered alone, or in combination with radiation, surgery or
chemotherapeutic agents. An isomer or analog of monoterpene or
sesquiterpene, or its derivative, may also be co-administered with
antiviral agents, anti-inflammatory agents or antibiotics. The
agents may be administered concurrently or sequentially. The
compounds of the present invention can be administered before,
during or after the administration of the other active
agent(s).
[0070] The compounds and methods of the present invention may used
to inhibit the Ras protein. The Ras family is a protein family of
small GTPases that are involved in cellular signal transduction.
Activation of Ras signaling causes cell growth, differentiation and
survival. Mtations in ras genes can permanently activate it and
cause inappropriate transmission inside the cell even in the
absence of extracellular signals. Because these signals result in
cell growth and division, dysregulated Ras signaling can ultimately
lead to oncogenesis and cancer. Activating mutations in Ras are
found in 20-25% of all human tumors and up to 90% in specific tumor
types. Goodsell DS (1999). Downward J., "The molecular perspective:
the ras oncogene". Oncologist 4 (3): 263-4. (January 2003).
"Targeting RAS signalling pathways in cancer therapy". Nat. Rev.
Cancer 3 (1): 11-22. Ras family members include, but are not
limited to, HRAS; KRAS; NRAS; DIRAS1; DIRAS2; DIRAS3; ERAS; GEM;
MRAS; NKIRAS1; NKIRAS2; NRAS; RALA; RALB; RAP1A; RAP1B; RAP2A;
RAP2B; RAP2C; RASD1; RASD2; RASL10A; RASL10B; RASL11A; RASL11B;
RASL12; REM1; REM2; RERG; RERGL; RRAD; RRAS; and RRAS. Wennerberg
K, Rossman KL, Der CJ (March 2005). "The Ras superfamily at a
glance". J. Cell. Sci. 118 (Pt 5): 843-6.
[0071] The isomer or analog of monoterpene or sesquiterpene, or a
derivative of the isomer or analog of monoterpene or sesquiterpene,
may be used in combination with radiation therapy. In one
embodiment, the present invention provides for a method of treating
tumor cells, such as malignant glioma cells, with radiation, where
the cells are treated with an effective amount of an isomer or
analog of monoterpene or sesquiterpene (or its derivative), such as
isoperillyl alcohol, and then exposed to radiation. Treatment by
the compounds of the present invention may be before, during and/or
after radiation. For example, the compounds of the present
invention may be administered continuously beginning one week prior
to the initiation of radiotherapy and continued for two weeks after
the completion of radiotherapy. U.S. Pat. Nos. 5,587,402 and
5,602,184.
[0072] In one embodiment, the present invention provides for a
method of treating tumor cells, such as malignant glioma cells,
with chemotherapy, where the cells are treated with an effective
amount of an isomer or analog of monoterpene or sesquiterpene (or a
derivative of the isomer or analog of monoterpene or
sesquiterpene), such as isoperillyl alcohol, and then exposed to
chemotherapy. Treatment by the compounds of the present invention
may be before, during and/or after chemotherapy.
[0073] The compounds of the present invention may be used for the
treatment of nervous system cancers, such as a malignant glioma
(e.g., astrocytoma, anaplastic astrocytoma, glioblastoma
multiforme), retinoblastoma, pilocytic astrocytomas (grade I),
meningiomas, metastatic brain tumors, neuroblastoma, pituitary
adenomas, skull base meningiomas, and skull base cancer. As used
herein, the term "nervous system tumors" refers to a condition in
which a subject has a malignant proliferation of nervous system
cells.
[0074] Cancers that can be treated by the present compounds
include, but are not limited to, lung cancer, ear, nose and throat
cancer, leukemia, colon cancer, melanoma, pancreatic cancer,
mammary cancer, prostate cancer, breast cancer, hematopoietic
cancer, ovarian cancer, basal cell carcinoma, biliary tract cancer;
bladder cancer; bone cancer; breast cancer; cervical cancer;
choriocarcinoma; colon and rectum cancer; connective tissue cancer;
cancer of the digestive system; endometrial cancer; esophageal
cancer; eye cancer; cancer of the head and neck; gastric cancer;
intra-epithelial neoplasm; kidney cancer; larynx cancer; leukemia
including acute myeloid leukemia, acute lymphoid leukemia, chronic
myeloid leukemia, chronic lymphoid leukemia; liver cancer; lymphoma
including Hodgkin's and Non-Hodgkin's lymphoma; myeloma; fibroma,
neuroblastoma; oral cavity cancer (e.g., lip, tongue, mouth, and
pharynx); ovarian cancer; pancreatic cancer; prostate cancer;
retinoblastoma; rhabdomyosarcoma; rectal cancer; renal cancer;
cancer of the respiratory system; sarcoma; skin cancer; stomach
cancer; testicular cancer; thyroid cancer; uterine cancer; cancer
of the urinary system, as well as other carcinomas and sarcomas.
U.S. Pat. No. 7,601,355.
[0075] The present invention also provides methods of treating CNS
disorders, including, without limitation, primary degenerative
neurological disorders such as Alzheimer's, Parkinson's,
psychological disorders, psychosis and depression. Autism may also
be treated by the present compositions and methods. Treatment may
consist of the use of a compound of the present invention alone or
in combination with current medications used in the treatment of
Parkinson's, Alzheimer's, or psychological disorders.
[0076] The present invention also provides a method of improving
immunomodulatory therapy responses comprising the steps of exposing
cells to an effective amount of a compound of the present
invention, such as isoperillyl alcohol, before or during
immunomodulatory treatment. Preferred immunomodulatory agents are
cytokines, such interleukins, lymphokines, monokines, interfereons
and chemokines.
[0077] The present composition may be administered by any method
known in the art, including, without limitation, intranasal, oral,
transdermal, ocular, intraperitoneal, inhalation, intravenous, ICV,
intracisternal injection or infusion, subcutaneous, implant,
vaginal, sublingual, urethral (e.g., urethral suppository),
subcutaneous, intramuscular, intravenous, rectal, sub-lingual,
mucosal, ophthalmic, spinal, intrathecal, intra-articular,
intra-arterial, sub-arachinoid, bronchial and lymphatic
administration. Topical formulation may be in the form of gel,
ointment, cream, aerosol, etc; intranasal formulation can be
delivered as a spray or in a drop; transdermal formulation may be
administered via a transdermal patch or iontorphoresis; inhalation
formulation can be delivered using a nebulizer or similar device.
Compositions can also take the form of tablets, pills, capsules,
semisolids, powders, sustained release formulations, solutions,
suspensions, elixirs, aerosols, or any other appropriate
compositions.
[0078] To prepare such pharmaceutical compositions, one or more of
compound of the present invention may be mixed with a
pharmaceutical acceptable carrier, adjuvant and/or excipient,
according to conventional pharmaceutical compounding techniques.
Pharmaceutically acceptable carriers that can be used in the
present compositions encompass any of the standard pharmaceutical
carriers, such as a phosphate buffered saline solution, water, and
emulsions, such as an oil/water or water/oil emulsion, and various
types of wetting agents. The compositions can additionally contain
solid pharmaceutical excipients such as starch, cellulose, talc,
glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk,
silica gel, magnesium stearate, sodium stearate, glycerol
monostearate, sodium chloride, dried skim milk and the like. Liquid
and semisolid excipients may be selected from glycerol, propylene
glycol, water, ethanol and various oils, including those of
petroleum, animal, vegetable or synthetic origin, e.g., peanut oil,
soybean oil, mineral oil, sesame oil, etc. Liquid carriers,
particularly for injectable solutions, include water, saline,
aqueous dextrose, and glycols. For examples of carriers,
stabilizers and adjuvants, see Remington's Pharmaceutical Sciences,
edited by E. W. Martin (Mack Publishing Company, 18th ed., 1990).
The compositions also can include stabilizers and
preservatives.
[0079] As used herein, the term "therapeutically effective amount"
is an amount sufficient to treat a specified disorder or disease or
alternatively to obtain a pharmacological response treating a
disorder or disease. Methods of determining the most effective
means and dosage of administration can vary with the composition
used for therapy, the purpose of the therapy, the target cell being
treated, and the subject being treated. Treatment dosages generally
may be titrated to optimize safety and efficacy. Single or multiple
administrations can be carried out with the dose level and pattern
being selected by the treating physician. Suitable dosage
formulations and methods of administering the agents can be readily
determined by those of skill in the art. For example, the
composition are administered at about 0.01 mg/kg to about 200
mg/kg, about 0.1 mg/kg to about 100 mg/kg, or about 0.5 mg/kg to
about 50 mg/kg. When the compounds described herein are
co-administered with another agent or therapy, the effective amount
may be less than when the agent is used alone.
[0080] Transdermal formulations may be prepared by incorporating
the active agent in a thixotropic or gelatinous carrier such as a
cellulosic medium, e.g., methyl cellulose or hydroxyethyl
cellulose, with the resulting formulation then being packed in a
transdermal device adapted to be secured in dermal contact with the
skin of a wearer. If the composition is in the form of a gel, the
composition may be rubbed onto a membrane of the patient, for
example, the skin, preferably intact, clean, and dry skin, of the
shoulder or upper arm and or the upper torso, and maintained
thereon for a period of time sufficient for delivery of the present
compound to the blood serum of the patient. The composition of the
present invention in gel form may be contained in a tube, a sachet,
or a metered pump. Such a tube or sachet may contain one unit dose,
or more than one unit dose, of the composition. A metered pump may
be capable of dispensing one metered dose of the composition.
[0081] This invention also provides the compositions as described
above for intranasal administration. As such, the compositions can
further comprise a permeation enhancer. Southall et al.
Developments in Nasal Drug Delivery, 2000. The present compound may
be administered intranasally in a liquid form such as a solution,
an emulsion, a suspension, drops, or in a solid form such as a
powder, gel, or ointment.
[0082] Devices to deliver intranasal medications are well known in
the art. Nasal drug delivery can be carried out using devices
including, but not limited to, intranasal inhalers, intranasal
spray devices, atomizers, nasal spray bottles, unit dose
containers, pumps, droppers, squeeze bottles, nebulizers, metered
dose inhalers (MDI), pressurized dose inhalers, insufflators, and
bi-directional devices. The nasal delivery device can be metered to
administer an accurate effective dosage amount to the nasal cavity.
The nasal delivery device can be for single unit delivery or
multiple unit delivery. In a specific example, the ViaNase
Electronic Atomizer from Kurve Technology (Bethell, Wash.) can be
used in this invention (http://www.kurvetech.com). The compounds of
the present invention may also be delivered through a tube, a
catheter, a syringe, a packtail, a pledget, a nasal tampon or by
submucosal infusion. U.S. Patent Publication Nos. 20090326275,
20090291894, 20090281522 and 20090317377.
[0083] The present compound can be formulated as aerosols using
standard procedures. The compound may be formulated with or without
solvents, and formulated with or without carriers. The formulation
may be a solution, or may be an aqueous emulsion with one or more
surfactants. For example, an aerosol spray may be generated from
pressurized container with a suitable propellant such as,
dichlorodifluoromethane, trichlorofluoromethane,
dichlorotetrafluoroethane, hydrocarbons, compressed air, nitrogen,
carbon dioxide, or other suitable gas. The dosage unit can be
determined by providing a valve to deliver a metered amount. Pump
spray dispensers can dispense a metered dose or a dose having a
specific particle or droplet size. As used herein, the term
"aerosol" refers to a suspension of fine solid particles or liquid
solution droplets in a gas. Specifically, aerosol includes a
gas-borne suspension of droplets of a monoterpene (or
sesquiterpene), as may be produced in any suitable device, such as
an MDI, a nebulizer, or a mist sprayer. Aerosol also includes a dry
powder composition of the composition of the instant invention
suspended in air or other carrier gas. Gonda (1990) Critical
Reviews in Therapeutic Drug Carrier Systems 6:273-313. Raeburn et
al., (1992) Pharmacol. Toxicol. Methods 27:143-159.
[0084] The present compound may be delivered to the nasal cavity as
a powder in a form such as microspheres delivered by a nasal
insufflator. The present compound may be absorbed to a solid
surface, for example, a carrier. The powder or microspheres may be
administered in a dry, air-dispensable form. The powder or
microspheres may be stored in a container of the insufflator.
Alternatively the powder or microspheres may be filled into a
capsule, such as a gelatin capsule, or other single dose unit
adapted for nasal administration.
[0085] The pharmaceutical composition can be delivered to the nasal
cavity by direct placement of the composition in the nasal cavity,
for example, in the form of a gel, an ointment, a nasal emulsion, a
lotion, a cream, a nasal tampon, a dropper, or a bioadhesive strip.
In certain embodiments, it can be desirable to prolong the
residence time of the pharmaceutical composition in the nasal
cavity, for example, to enhance absorption. Thus, the
pharmaceutical composition can optionally be formulated with a
bioadhesive polymer, a gum (e.g., xanthan gum), chitosan (e.g.,
highly purified cationic polysaccharide), pectin (or any
carbohydrate that thickens like a gel or emulsifies when applied to
nasal mucosa), a microsphere (e.g., starch, albumin, dextran,
cyclodextrin), gelatin, a liposome, carbamer, polyvinyl alcohol,
alginate, acacia, chitosans and/or cellulose (e.g., methyl or
propyl; hydroxyl or carboxy; carboxymethyl or hydroxylpropyl).
[0086] The composition containing the present compound can be
administered by oral inhalation-into the respiratory tract, i.e.,
the lungs.
[0087] Typical delivery systems for inhalable agents include
nebulizer inhalers, dry powder inhalers (DPI), and metered-dose
inhalers (MDI).
[0088] Nebulizer devices produce a stream of high velocity air that
causes a therapeutic agent in the form of liquid to spray as a
mist. The therapeutic agent is formulated in a liquid form such as
a solution or a suspension of particles of suitable size. In one
embodiment, the particles are micronized. The term "micronized" is
defined as having about 90% or more of the particles with a
diameter of less than about 10 .mu.m. Suitable nebulizer devices
are provided commercially, for example, by PARI GmbH (Starnberg,
Germany). Other nebulizer devices include Respimat (Boehringer
Ingelheim) and those disclosed in, for example, U.S. Pat. Nos.
7,568,480 and 6,123,068, and WO 97/12687. The present compound can
be formulated for use in a nebulizer device as an aqueous solution
or as a liquid suspension.
[0089] DPI devices typically administer a therapeutic agent in the
form of a free flowing powder that can be dispersed in a patient's
air-stream during inspiration. DPI devices which use an external
energy source may also be used in the present invention. In order
to achieve a free flowing powder, the present compound can be
formulated with a suitable excipient (e.g., lactose). A dry powder
formulation can be made, for example, by combining dry lactose
having a particle size between about 1 .mu.m and 100 .mu.m with
micronized particles of the present compound and dry blending.
Alternatively, the compound can be formulated without excipients.
The formulation is loaded into a dry powder dispenser, or into
inhalation cartridges or capsules for use with a dry powder
delivery device. Examples of DPI devices provided commercially
include Diskhaler (GlaxoSmithKline, Research Triangle Park, N.C.)
(see, e.g., U.S. Pat. No. 5,035,237); Diskus (GlaxoSmithKline)
(see, e.g., U.S. Pat. No. 6,378,519; Turbuhaler (AstraZeneca,
Wilmington, Del.) (see, e.g., U.S. Pat. No. 4,524,769); and
Rotahaler (GlaxoSmithKline) (see, e.g., U.S. Pat. No. 4,353,365).
Further examples of suitable DPI devices are described in U.S. Pat.
Nos. 5,415,162, 5,239,993, and 5,715,810 and references
therein.
[0090] MDI devices typically discharge a measured amount of the
stored composition using compressed propellant gas. Formulations
for MDI administration include a solution or suspension of an
active ingredient in a liquefied propellant. Examples of
propellants include hydrofluoroalklanes (HFA), such as
1,1,1,2-tetrafluoroethane (HFA 134a) and
1,1,1,2,3,3,3-heptafluoro-n-propane (HFA 227), and
chlorofluorocarbons, such as CCl.sub.3F. Additional components of
HFA formulations for MDI administration include co-solvents, such
as ethanol, pentane, water; and surfactants, such as sorbitan
trioleate, oleic acid, lecithin, and glycerin. (See, for example,
U.S. Pat. No. 5,225,183, EP 0717987, and WO 92/22286). The
formulation is loaded into an aerosol canister, which forms a
portion of an MDI device. Examples of MDI devices developed
specifically for use with HFA propellants are provided in U.S. Pat.
Nos. 6,006,745 and 6,143,227. For examples of processes of
preparing suitable formulations and devices suitable for inhalation
dosing see U.S. Pat. Nos. 6,268,533, 5,983,956, 5,874,063, and
6,221,398, and WO 99/53901, WO 00/61108, WO 99/55319 and WO
00/30614.
[0091] The present compound may be encapsulated in liposomes or
microcapsules for delivery via inhalation. A liposome is a vesicle
composed of a lipid bilayer membrane and an aqueous interior. The
lipid membrane may be made of phospholipids, examples of which
include phosphatidylcholine such as lecithin and lysolecithin;
acidic phospholipids such as phosphatidylserine and
phosphatidylglycerol; and sphingophospholipids such as
phosphatidylethanolamine and sphingomyelin. Alternatively,
cholesterol may be added. A microcapsule is a particle coated with
a coating material. For example, the coating material may consist
of a mixture of a film-forming polymer, a hydrophobic plasticizer,
a surface activating agent or/and a lubricant nitrogen-containing
polymer. U.S. Pat. Nos. 6,313,176 and 7,563,768.
[0092] The present compound may also be used alone or in
combination with other chemotherapeutic agents via topical
application for the treatment of localized cancers such as breast
cancer or melanomas. The present compound may also be used in
combination with narcotics or analgesics for transdermal delivery
of pain medication.
[0093] This invention also provides the compositions as described
above for ocular administration. As such, the compositions can
further comprise a permeation enhancer. For ocular administration,
the compositions described herein can be formulated as a solution,
emulsion, suspension, etc. A variety of vehicles suitable for
administering compounds to the eye are known in the art. Specific
non-limiting examples are described in U.S. Pat. Nos. 6,261,547;
6,197,934; 6,056,950; 5,800,807; 5,776,445; 5,698,219; 5,521,222;
5,403,841; 5,077,033; 4,882,150; and 4,738,851.
[0094] The present compound can be given alone or in combination
with other drugs for the treatment of the above diseases for a
short or prolonged period of time. The present compositions can be
administered to a mammal, preferably a human. Mammals include, but
are not limited to, murines, rats, rabbit, simians, bovines, ovine,
porcine, canines, feline, farm animals, sport animals, pets,
equine, and primates.
[0095] The invention also provides a method for inhibiting the
growth of a cell in vitro, cx vivo or in vivo, where a cell, such
as a cancer cell, is contacted with an effective amount of the
present compound as described herein.
[0096] Pathological cells or tissue such as hyperproliferative
cells or tissue may be treated by contacting the cells or tissue
with an effective amount of a composition of this invention. The
cells, such as cancer cells, can be primary cancer cells or can be
cultured cells available from tissue banks such as the American
Type Culture Collection (ATCC). The pathological cells can be cells
of a systemic cancer, gliomas, meningiomas, pituitary adenomas, or
a CNS metastasis from a systemic cancer, lung cancer, prostate
cancer, breast cancer, hematopoietic cancer or ovarian cancer. The
cells can be from a vertebrate, preferably a mammal, more
preferably a human. U.S. Patent Publication No. 2004/0087651.
Balassiano et al. (2002) Intern. J. Mol. Med. 10:785-788. Thorne,
et al. (2004) Neuroscience 127:481-496. Fernandes, et al. (2005)
Oncology Reports 13:943-947. Da Fonseca, et al. (2008) Surgical
Neurology 70:259267. Da Fonseca, et al. (2008) Arch. lmmunol. Ther.
Exp. 56:267-276. Hashizume, et al. (2008) Neuroncology
10:112-120.
[0097] In vitro efficacy of the present composition can be
determined using methods well known in the art. For example, the
cytoxicity of the present compound may be studied by MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide]
cytotoxicity assay. MTT assay is based on the principle of uptake
of MTT, a tetrazolium salt, by metabolically active cells where it
is metabolized into a blue colored formazon product, which can be
read spectrometrically. J. of Immunological Methods 65: 55 63,
1983. The cytoxicity of the present compound may be studied by
colony formation assay. Functional assays for inhibition of VEGF
secretion and IL-8 secretion may be performed via ELISA. Cell cycle
block by the present compound may be studied by standard propidium
iodide (PI) staining and flow cytometry. Invasion inhibition may be
studied by Boyden chambers. In this assay a layer of reconstituted
basement membrane, Matrigel, is coated onto chemotaxis filters and
acts as a barrier to the migration of cells in the Boyden chambers.
Only cells with invasive capacity can cross the Matrigel barrier.
Other assays include, but are not limited to, cell viability
assays, apoptosis assays, and morphological assays.
[0098] The following are examples of the present invention and are
not to be construed as limiting.
EXAMPLES
Example 1
Synthesis of Iso-POH
[0099] The reaction scheme is the following:
##STR00041##
Preparation of 4-isopropylidene-1,4-dioxa-spiro[4.5] decane (2)
[0100] Isopropyltriphenylphosphonium iodide (83.02 g, 192 mmol) was
added to NaH (60%, in mineral oil, 8.38 g, 192 mmol) in dry
dimethyl sulfoxide (120 mL) at room temperature under a nitrogen
atmosphere. The reaction mixture was slowly heated to 50.degree. C.
over a period of 15 min and maintained at 50.degree. C. until the
reaction mass became a red color (approximately 30 min). A solution
of 1,4-cyclohexanedione monoethylene ketal (1, 30 g, 192 mmol) in
dry dimethyl sulfoxide was added over a period of 45 min while
keeping the temperature below 50.degree. C. and the reaction was
maintained at 50.degree. C. for 16 h. The reaction mixture was
cooled to room temperature, quenched with cold water (150 ml), and
extracted with ethyl acetate (2.times.160 mL). The combined organic
layer was washed with water (2.times.200 mL), followed by brine
(10%, 250 mL) and dried over sodium sulfate. The filtered organic
layer was concentrated to give a solid which was triturated with
hexanes (300 mL) and the precipitated triphenylphosphine oxide was
filtered off. The hexane layer was concentrated to give an oil
which was purified by column chromatography. [Column dimensions:
dia: 6.0 cm, height: 12 cm, silica: 200 mesh, eluted hexanes (1.0
L) followed by hexane: ethyl acetate (97:3, 2.0 L)] The hexane:
ethyl acetate fractions were combined and concentrated under vacuum
to give an oil. Weight: 23.36 g. Weight yield: 66.7%. .sup.1H-NMR
(400 MHz, CDCl.sub.3): .delta. 1.61-1.63 (t, 4H), 1.64 (s, 6H),
2.29 (m, 4H), 3.97 (s, 4H). MS (APCI method): No molecular ion peak
was observed.
Preparation of 4-isopropylidene cyclohexanone (3)
[0101] p-Toluenesulfonic acid (31.16 g, 164 mmol) was added to a
solution of ketal (2, 23.0 g, 126 mmol) in acetone (2.3 L) and
water (138 mL). The reaction mixture was heated to reflux and
maintained at reflux for 3.5 h. The mixture was cooled to room
temperature, treated with saturated sodium bicarbonate (60 mL) and
concentrated under vacuum. The resulting oily residue was extracted
with ethyl acetate (2.times.130 mL), washed with water (100 mL),
then brine (100 mL), and dried over sodium sulfate. The filtered
organic layer was concentrated under vacuum to give an oil. Weight:
16 g. Weight yield: 92%. .sup.1H-NMR (400 MHz, CDCl.sub.3): .delta.
1.69 (s, 6H), 2.35 (t, 4H), 2.50 (t, 4H). MS (APCI method): No
molecular ion peak was observed (Note: .sup.1H-NMR showed the
presence of .about.2% of ketal 2 but used without
purification).
Preparalion of 4-isopropylidene-1-oxa-spiro[2.5]octane (4)
[0102] Potassium t-butoxide (3.3 g, 29.4 mmol) was added to a
mixture of ketone (3, 2.5 g, 18.1 mmol) and trimethylsulfoxonium
iodide (6.45 g, 29.4 mmol) in dry dimethyl sulfoxide (40 mL) under
nitrogen atmosphere at room temperature. The mixture was stirred
for 4.0 h at room temperature. The reaction was quenched by the
addition of cold water (40 mL) and extracted with ethyl acetate
(2.times.60 mL). The combined organic layer was washed with water
(75 mL) followed by brine (75 mL) and dried over sodium sulfate.
The filtered organic layer was concentrated under vacuum to give an
oil. Weight: 2.13 g. Weight yield: 77%. .sup.1H-NMR (400 MHz,
CDCl.sub.3): .delta. 1.42-1.50 (m, 2H), 1.55-1.61 (m, 2H), 1.65 (s,
6H), 2.31 (t, 4H), 2.61 (s, 2H). MS (APCI method): No molecular ion
peak was observed.
Preparation of 3,5-dinitrobenzoic acid 4-isopropylidene
cyclohex-1-enylmethyl ester (6)
[0103] Aluminum isopropoxide (5.93 g, 29.0 mmol) was added to a
mixture of epoxide (4, 4.0 g, 26.2 mmol) in toluene (80 mL) and the
mixture was heated to reflux for 7.0 h. The mixture was cooled to
room temperature and quenched with saturated potassium sodium
tartrate solution. The organic layer was separated, washed with
water (40 mL), followed by brine (40 mL), and dried over sodium
sulfate. The filtered organic layer was concentrated under vacuum
to give crude isoperillyl alcohol (5) as an oil. Weight: 4.0 g,
Weight yield: 100%, Purity: .about.85-90% (by GC area percent,
Actual yield ca: 85%).
[0104] Triethylamine (5.1 mL, 36.6 mmol) was added to a solution of
crude isoperillyl alcohol (5, 4.0 g, 26.2 mmol) in dichloromethane
(50 mL). After stirring for 15 min, 3,5-dinitrobenzoyl chloride
(6.3 g, 27.5 mmol) was added over a period of 0.25 h. The reaction
mixture was stirred for 3.0 h and quenched with water (30 mL). The
organic layer was separated, washed with water (40 mL), and dried
over sodium sulfate. The filtered organic layer was concentrated
under vacuum to give a pale yellow solid (8.5 g), which was
recrystallized from acetone to give pure ester 6 as a pale yellow
solid. Mp: 138-140.degree. C. (acetone). Weight: 5.7 g, Yield: 62%
(from epoxide). .sup.1H-NMR (400 MHz, CDCl.sub.3): .delta. 1.68 (s,
3H), 1.71 (s, 3H), 2.18 (t, 2H), 2.40 (t, 2H), 2.87 (br s, 2H),
4.85 (s, 2H); 5.88 (s, 1H), 9.17 (t, 1H), 9.24 (s, 1H). MS (APCI
method): m/e: 247.1 (5%), 149.07 (7%), 135.1 (100%), 107.1
(9%).
Preparation of isoperillyl alcohol (7)
[0105] Aqueous sodium hydroxide (1.43 g, 35.7 mmol, dissolved in
12.5 mL of water) was added to an ice cold solution of
3,5-dinitrobenzoic acid 4-isopropylidene-cyclohex-1-enylmethyl
ester (6, 5.63 g, 16.2 mmol) in methanol (56 mL) over a period of
0.25 h. The reaction mixture was allowed to warm to room
temperature and then stirred for 3.0 h. The methanol was
concentrated under vacuum to a minimum stirring volume and the
mixture was suspended in water (40 mL). The resulting mixture was
extracted with ethyl acetate (2.times.50 mL). The organic layer was
washed with water (2.times.50 mL), then brine (50 mL), and dried
over sodium sulfate. The filtered organic layer was concentrated
under vacuum to give pure isoperillyl alcohol as an oil. Weight:
2.35 g, Yield: 95%, Purity: 97% (by GC AUC). .sup.1H-NMR (400 MHz,
CDCl.sub.3): .delta. 1.65 (s, 3H), 1.69 (s, 3H), 1.77 (bs, OH),
2.09 (m, 2H), 2.33 (t, 2H), 2.79 (br s, 2H); .sup.13C-NMR: .delta.
20.38, 20.80, 26.95, 27.60, 29.86, 67.49, 122.88, 123.04, 127.92,
138.37. MS (APCI method): m/e: 152 (M.sup.+, 3.5%), 135.07 (100%),
107.12 (5%). However, the mass spectrum showed four small peaks
(.about.5%) at M+: 207.06, 269.1, 287.09 & 301 which were not
characterized.
Example 2
Alternative Synthesis of Iso-POH
[0106] The reaction scheme is the following:
##STR00042##
Preparation of trifluoromethanesulfonic acid
4-isopropylidenecyclohex-1-enyl ester (8)
[0107] 2.5 M solution of n-Butyl lithium in hexanes (5.6 mL, 14.1
mmol) was added to a solution of diisopropylamine (1.98 mL, 14.1
mmol) in dry THF (30 mL) at -78.degree. C. over a period of 0.5 hr.
After stirring for 1.0 h at -78.degree. C., a solution of ketone
(3, 1.3 g, 9.4 mmol) in dry THF (10 mL) was added over a period of
10 min while maintaining the temperature below -78.degree. C. The
reaction mixture was stirred for 1.0 h at -78.degree. C. A solution
of phenyltriflimide (3.53 g, 9.86 mmol) in THF (15 mL) was added
slowly while maintaining the temperature below -78.degree. C. The
reaction mixture was slowly warmed to 0.degree. C., maintained for
2.0 h at 0.degree. C. and then quenched with satd ammonium chloride
solution. The separated organic layer was washed with water (15
mL), brine (15 mL) and dried over sodium sulfate. The filtered
organic layer was concentrated under vacuum and the resulting
residue was purified by column chromatography. [Column dimensions:
dia: 6.0 cm, height: 12 cm, silica: 200 mesh, eluted with hexanes
(200 mL)] The similar fractions were combined and concentrated
under vacuum which gave an oil. Weight: 0.9 g. Weight yield: 38%.
.sup.1H-NMR (400 MHz, CDCl.sub.3): .delta. 1.68 (s, 3H), 1.71 (s,
3H), 2.37 (m, 2H), 2.46 (m, 2H), 2.91 (m, 2H), 5.73 (m, 1H). MS
(APCI method): No molecular ion peak was observed.
[0108] Note-1: .sup.1H-NMR indicated the presence of aromatic peaks
(.about.5%) between .delta. 7.42-7.57 which were attributed to the
by-product trifluoro-N-phenylmethanesulfonamide.
[0109] Note-2: The compound 8 was also synthesized in low yield
(28%) using triflic anhydride in the presence of
2,6-di-tert-butyl-4-methylpyridine as a base.
Preparation of 4-isopropylidene cyclohex-1-enecarboxylic acid
methyl ester (9)
[0110] To a solution of compound 8 (0.2 g, 0.74 mmol) in
N'N-dimethylformamide (1.5 mL) was added methanol (1.0 mL),
triethylamine (0.17 mL, 1.2 mmol),
1,3-bis(diphenylphosphino)propane (0.03 g, 0.07 mmol) and palladium
acetate (0.04 g, 0.07 mmol). The reaction mixture was degassed and
then stirred at room temperature under carbon monoxide (balloon
pressure) for 5 h. The reaction mixture was diluted with ethyl
acetate (15 mL) and washed with 0.5 N HCl (15 mL), brine (15 mL)
and dried over sodium sulfate. The filtered organic layer was
concentrated under vacuum and the resulting residue was purified by
column chromatography. [Column dimensions: dia: 6.0 cm, height: 12
cm, silica: 200 mesh, eluted with hexanes (100 mL) followed by
ethyl acetate: hexanes (2%, 150 mL)] The similar fractions were
combined and concentrated under vacuum which gave an oil. While TLC
analysis showed only a single spot, .sup.1H-NMR and GC analysis
indicated that the isolated material was a mixture of two primary
components that co-eluted by TLC. Weight: 0.11 g. Weight yield:
82%. .sup.1H-NMR (400 MHz, CDCl.sub.3) indicated the presence of
peaks corresponding to the methyl ester (9) along with an unknown
impurity. GC analysis confirmed that it is mainly a mixture of two
compounds with a ratio of 3:1. MS (APCI method): m/e: 180 (M.sup.-,
5%), 180.9 (M.sup.+1, 100%). The other peaks 5%) at M+: 197.8,
247.0 & 274.0 were not characterized. The crude mixture was
taken forward without purification.
[0111] Preparation of isoperillyl alcohol (7): Methyl ester (9,
0.11 g, 0.6 mmol) in dry THF (10 mL) was added to a cold solution
of LAH (0.03 g, 0.78 mmol) in dry THF (10 mL) over a period of 2
min. The reaction mixture was slowly heated to reflux and
maintained for 3.0 h. The mixture was cooled to 5.degree. C. and
quenched with satd sodium sulfate (1.5 mL). The precipitated
lithium salts were filtered off and washed with hot ethyl acetate
(20 mL). The filtrate was dried over sodium sulfate. The filtered
organic layer was concentrated under vacuum which gave an oil.
Weight: 74 mg. Weight yield: 79%. While TLC analysis showed only a
single spot, .sup.1H-NMR and GC analysis indicated that the
isolated material was a mixture of two primary components that
co-eluted by TLC. .sup.1H-NMR (400 MHz, CDCl.sub.3) indicated the
presence of peaks corresponding to the isoperillyl alcohol (7)
along with an unknown impurity. MS (APCI method): m/e: 153
(M.sup.+1, 40%), 152 (M.sup.+, 13%), 135.09 (M-OH). The other peaks
at M+: 169.03 (10%), 255.20, (13%), 285.25 (15%), 287.19 (70%), 290
(68%), & 397.24 (15%) were not characterized. GC analysis
confirmed the presence of isoperillyl alcohol (20.5%, (AUC)),
compared with the iso-POH obtained from the epoxide route along
with the unknown impurity (67.5%, (AUC)).
Example 3
In Vitro Cytotoxicity Studies of Iso-POH ((4-Isopropylidene
cyclohex-1-enyl)-methanol)
[0112] The MTT cytotoxicity assays were carried out after cells
were treated with iso-POH (e.g., synthesized by the method in
Example 1) or other types of POH with different purity. FIG. 1
shows the results of the MTT cytotoxicity assays demonstrating the
efficacy of different types of POH and iso-POH in killing LN229
human glioma cells. Sigma POH is the POH purchased from Sigma
Chemicals having a purity of about 96%. SGP-527-155 was prepared
from the WAKO POH by two-fold crystallization from di-isopropyl
ether solvent, and has a GC relative area purity of about 98.7%
(area under the curve). KWH0744 is the crude POH purchased from
Wako having a purity of about 89.5%. SGP-527-130 was prepared from
the WAKO POH by single crystallization from di-isopropyl ether
solvent, and has a GC relative area purity of about 97.1% (area
under the curve). FIG. 2 shows the results of the MTT cytotoxicity
assays demonstrating the efficacy of different types of POH and
iso-POH in killing U251 human glioma cells. FIG. 3 shows the
results of the MTT cytotoxicity assays demonstrating the efficacy
of different types of POH and iso-POH in killing A172 human glioma
cells. The results suggest that iso-POH exhibited much better
cytotoxicity than POH with different purity.
[0113] In vitro cytotoxicity of iso-POH in temozolomide-sensitive
or temozolomide-resistant cells were also studied. Glioma cells
were treated with Sigma POH, POH synthesized to GLP quality
(SGP-527-155) having a purity of about 98.7%, and iso-POH
(SGP-561-79P, SGP-561-65P) for 48 hours and MTT assay performed.
FIG. 4 demonstrates that A172 cells had the greatest cytotoxic
response to iso-POH compared to GLP POH and Sigma POH (FIG. 4A).
This response pattern was also seen in A172 temozolomide resistant
cells (FIG. 4B). Similarly, FIG. 5 demonstrates that U251 cells had
the greatest response to iso-POH (FIG. 5A), and that this response
was also seen in U251 temozolomide resistant cells (FIG. 5B). The
same response to iso-POH was seen in LN229 temozolomide sensitive
(FIG. 6A) and temozolomide resistant cells (FIG. 6B). U87 cells,
both temozolomide sensitive (FIG. 7A) and resistant (FIG. 7B), had
the greatest response to iso-POH, albeit less than LN229 and U251
cells.
[0114] FIG. 8 shows the results of the MTT assays performed using
TMZ sensitive U251 glioma cells over 24 hours using Sigma POH, GLP
POH having a purity of about 98.7%, iso-POH (Iso-POH65, Iso-POH79)
all at 0 mM-3 mM concentration. Iso-POH had greater cytotoxicity
compared to Sigma POH and GLP POH (FIG. 8A). U251 temozolomide
resistant cell line (U251-TR2) treated under same conditions
demonstrated greater cytotoxicity with iso-POH compared to Sigma
and GLP POH (FIG. 8B). Another U251 temozolomide resistant cell
line (U251-TR1) treated under same conditions also demonstrated
greater cytotoxicity with iso-POH (iso-POH65, iso-POH79) compared
to GLP POH or Sigma POH (FIG. 8C).
[0115] FIG. 9 shows the results of the MIT assay performed using
glioblastoma cancer stem cell line USC04 treated with both GLP-POH
and iso-POH (Iso-POH65) over 24 hrs. GLP POH and iso-POH
demonstrated similar cytoxicity on the cells.
[0116] U251 TMZ-sensitive and TMZ-resistant (U251-TR1, U251-TR2)
cells were treated with Sigma POH (1.5 mM) or GLP POH (1.5 mM) for
18 hours, then Western blot was performed. The results show that
Sigma POH and GLP POH increased expression of glucose-regulatory
protein 78 (GRP-78) and the apoptosis marker CHOP, suggesting
increased endoplasmic reticulum (ER) stress after treatment (FIG.
10a). Under the same conditions, iso-POH (iso-POH65, iso-POH79)
also increased ER stress (FIG. 10b).
[0117] U251 glioma cells were treated with 500 .mu.M Sigma POH, GLP
POH or iso-POH (isoPOH65, isoPOH79) for 24 hours, then Western blot
was performed. The results (FIG. 11) demonstrate that all
treatments decreased Kras expression.
Example 4
Synthesis of Iso-POH Conjugated with Temozolamide (TMZ)
[0118] The reaction scheme is the following:
##STR00043##
Preparation of
(3-Methyl4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carbonyl)-ca-
rbamic acid-4-isopropylidene cyclohex-1-enylmethyl ester
[0119] Oxalyl chloride (0.26 g, 2.0 mmol) will be added slowly to a
mixture of Temozolamide (Source: OChem Incorporation, Lot
#0711185A; 0.2 g, 1.0 mmol) in 1,2-dichloroethane (15 mL) over a
period of 5 min while maintaining the temperature at 10.degree. C.
under N.sub.2. The reaction mixture will be allowed to warm to room
temperature and then heated to reflux for 2.5 h. The excess of
oxalyl chloride and 1,2-dichloroethane will be removed by
concentration under vacuum. The resulting residue will be
redissolved in 1,2-dichloroethane (20 mL) and the reaction mixture
cooled to 5.degree. C. under N2. A solution of isoperillyl alcohol
(0.17 g, 1.12 mmol) in 1,2-dichloroethane (5 mL) will be added over
a period of 10 min. The reaction mixture will be allowed to warm to
room temperature and stirred for 12 h. 1,2-Dichloroethane will be
concentrated under vacuum to give a residue which will be
triturated with hexanes. The resulting pale yellow solid will be
filtered and washed with hexanes.
Example 5
Synthesis of Iso-POH Conjugated with Rolipram
[0120] The reaction scheme is as follows.
##STR00044##
Preparation of
4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-oxo-pyrrolidine-1-carboxylic
acid 4-isopropylidene cyclohex-1-enylmethyl ester
[0121] Phosgene (20% in toluene, 19.5 ml, 39.4 mmol) will be added
to a mixture of isoperillyl alcohol (3.0 g, 19.7 mmol) and
potassium carbonate (8.1 g, 58.6 mmol) in dry toluene (45 mL) over
a period of 45 min while maintaining the temperature between
10-12.degree. C. The reaction mixture will be allowed to warm to
room temperature and stirred for 10 h under N.sub.2. The reaction
mixture will be quenched with water (40 mL) and the organic layer
separated. The aqueous layer will be extracted with toluene (30 mL)
and the combined organic layer washed with water (40 mL.times.2),
brine (10%, 40 mL), and dried over sodium sulfate (25 g). The
filtered organic layer will be concentrated under vacuum to give
isoperillyl chloroformate as an oil.
[0122] Butyl lithium (2.5 M, 0.36 mL, 0.90 mmol) will be added to a
solution of rolipram (Source: GL synthesis, Inc. Lot
#GLS-SH-110809; 0.2 g, 0.72 mmol) in dry THF (8 mL) at -72.degree.
C. over a period of 10 min under N.sub.2. After the reaction
mixture being stirred for 1.0 h at -72.degree. C., isoperillyl
chloroformate (0.16 g, 0.76 mmol, dissolved in 4 mL THF) will be
added over a period of 10 min while maintaining the temperature at
-72.degree. C. The reaction mixture will be stirred for 3 h and
quenched with saturated ammonium chloride (10 mL). The reaction
mixture will be allowed to warm to room temperature and extracted
with ethyl acetate (2.times.20 mL). The combined organic layer will
be washed with water (20 mL), brine (10%, 25 mL), and dried over
sodium sulfate. The filtered organic layer will be concentrated to
give an oil which will be purified by column chromatography [Column
dimensions: dia: 1.5 cm, height: 15 cm, silica: 230-400 mesh] and
eluted with a mixture of 5% ethyl acetate/hexanes (120 mL) followed
by 10% ethyl acetate/hexanes (150 mL). The 10% ethyl acetate
/hexanes fractions will be combined and concentrated under vacuum
to give a gummy solid.
Example 6
Synthesis of Dimethyl Celecoxib bis iso-POH carbamate conjugate
[0123] The reaction scheme is as follows.
##STR00045##
Preparation of 4-(Bis-N,N'-4-isopropylidene
cyclohex-1-enylmethyloxy carbonyl [5-(2,5-dimethyl
phenyl)-3-trifluoromethyl pyrazol-1-yl]benzenesulfonamide
[0124] Phosgene (20% in toluene, 19.5 ml, 39.4 mmol) will be added
to a mixture of isoperillyl alcohol (3.0 g, 19.7 mmol) and
potassium carbonate (8.1 g, 58.6 mmol) in dry toluene (45 mL) over
a period of 45 min while maintaining the temperature between
10-12.degree. C. The reaction mixture will be allowed to warm to
room temperature and stirred for 10 h under N.sub.2. The reaction
mixture will be quenched with water (40 mL) and the organic layer
separated. The aqueous layer will be extracted with toluene (30 mL)
and the combined organic layer washed with water (40 mL.times.2),
brine (10%, 40 mL), and dried over sodium sulfate (25 g). The
filtered organic layer will be concentrated under vacuum to give
isoperillyl chloroformate as an oil.
[0125] Isoperillyl chloroformate (0.22 g, 1.0 mmol) will be added
slowly to a mixture of dimethyl celecoxib (0.2 g, 0.50 mmol) and
potassium carbonate (0.14 g, 1.0 mmol) in dry acetone (25 mL) over
a period of 5 min under N.sub.2. The reaction mixture will be
heated to reflux and maintained for 4 h. The reaction mixture will
be cooled and the acetone concentrated under vacuum. The resulting
residue will be suspended in water (25 mL) and extracted with ethyl
acetate (3.times.20 mL). The combined organic layer will be washed
with water (40 mL), followed by brine (10%, 30 mL), and dried over
sodium sulfate. The filtered organic layer will be concentrated
under vacuum to give a residue which will be purified by column
chromatography [Column dimensions: dia: 1.5 cm, height: 15 cm,
silica: 230-400 mesh] and eluted with hexanes (100 mL) followed by
a mixture of hexanes/ethyl acetate (95:5, 100 mL). The hexane/ethyl
acetate fractions will be combined and concentrated under vacuum to
give a gummy mass.
[0126] The scope of the present invention is not limited by what
has been specifically shown and described hereinabove. Those
skilled in the art will recognize that there are suitable
alternatives to the depicted examples of materials, configurations,
constructions and dimensions. Numerous references, including
patents and various publications, are cited and discussed in the
description of this invention. The citation and discussion of such
references is provided merely to clarify the description of the
present invention and is not an admission that any reference is
prior art to the invention described herein. All references cited
and discussed in this specification are incorporated herein by
reference in their entirety. Variations, modifications and other
implementations of what is described herein will occur to those of
ordinary skill in the art without departing from the spirit and
scope of the invention. While certain embodiments of the present
invention have been shown and described, it will be obvious to
those skilled in the art that changes and modifications may be made
without departing from the spirit and scope of the invention. The
matter set forth in the foregoing description and accompanying
drawings is offered by way of illustration only and not as a
limitation.
* * * * *
References